Nicotine abuse vaccine TA-NIC

Drug Profile

Nicotine abuse vaccine TA-NIC

Alternative Names: TA-NIC

Latest Information Update: 24 Aug 2011

Price : $50

At a glance

  • Originator ImmuLogic Pharmaceutical
  • Developer Celtic Pharma
  • Class Drug withdrawal therapies; Smoking cessation therapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Smoking withdrawal

Most Recent Events

  • 08 May 2006 Celtic Pharma has received approval to conduct a phase II trial for the treatment of smoking withdrawal in the UK
  • 07 Mar 2005 Data from a media release have been added to the Drug Withdrawl therapeutic trials and immunogenicity sections
  • 16 Jul 2004 Data from a media release have been added to the adverse events and Drug Withdrawal immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top